Wells Fargo analyst Derek Archila maintained a Hold rating on Incyte (INCY – Research Report) yesterday and set a price target of $58.00. The ...

Wells Fargo analyst Derek Archila maintained a Buy rating on aTyr Pharma (ATYR – Research Report) today and set a price target of $17.00. The ...

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Incyte Corporation (NASDAQ:INCY) stands against other ...

Shares of Incyte Corp. slid 8.62% to $62.01 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index rising 0.64% to 5,675.12 and the Dow Jones ...

HERZLIYA, Israel and CALGARY, AB, March 7, 2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") is pleased to announce that it has closed its ...

HERZLIYA, Israel and CALGARY, AB, March 7, 2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") is pleased to announce that it has closed its ...

In this article, we are going to take a look at where Incyte Corporation (NASDAQ ... especially in the realm of biotech and pharmaceutical companies. As the global demand for innovative treatments ...

AI biotech startup Genesis Therapeutics entered an agreement with pharmaceutical company Incyte to use Genesis’ AI drug discovery platform, GEMS, to discover small molecule drug candidates ...

Incyte/Novartis' JAKAFI and PharmaEssentia/AOP Orphan Pharmaceuticals' BESREMi. In contrast, we also anticipate the launch and potential uptake of a third product, Protagonist Therapeutics ...